LEO Pharma buys worldwide dersimelagon rights for up to $435 million
Danish drugmaker LEO Pharma said on Tuesday it had agreed to acquire worldwide rights to drug candidate dersimelagon from Tanabe Pharma for up to $435 million in up-front and near-term milestone payments.
KVH Industries Stock Slips Post Q2 Earnings, Revenues Up on LEO Growth
KVHI's LEO transition in second-quarter 2026 gains momentum as Starlink and OneWeb growth boost airtime revenues, while rising costs pressure profitability.
Amazon: Long-Term Bullish But Short-Term Neutral (Rating Downgrade)
Amazon.com, Inc. While demonstrating robust growth across all segments, CAPEX investments are weakening the short-term financial outlook, with the bet that the AWS success will repeat. As the firm is heading to launch Amazon LEO services, there are operational costs that are expected to contract margins in the medium term. Both AI and LEO CAPEX commitments will further contract FCF margins, which will result in the firm using cash at hand, drawing from the credit facility to further fund growth.
LEO: Tax-Free Yield And Measured Duration Exposure
BNY Mellon Strategic Municipals, Inc. is a closed-end fund primarily investing in investment-grade municipal tax-exempt debt with long-term maturity profiles. LEO's municipal bond fund offers an unsubsidized SEC yield of ~4.81%, which on a tax-equivalent basis equals ~8.13% for an investor in the highest tax bracket. The current elevated interest rate levels along with a higher term spread suggests some possibility of a medium-term mean reversion for the performances. The credit spreads however remain tighter.
